Two cases of eczematous eruptions caused by everolimus
暂无分享,去创建一个
[1] J. Hao,et al. RAD001 (everolimus) attenuates experimental autoimmune neuritis by inhibiting the mTOR pathway, elevating Akt activity and polarizing M2 macrophages , 2016, Experimental Neurology.
[2] A. Heiligenhaus,et al. Everolimus improves experimental autoimmune uveoretinitis. , 2012, Experimental eye research.
[3] R. Motzer,et al. Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors , 2012, Cancer.
[4] M. Lacouture,et al. Eosinophilic rash secondary to temsirolimus. , 2009, Clinical genitourinary cancer.
[5] F. Giles,et al. The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents , 2009, Targeted Oncology.
[6] R. Motzer,et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial , 2008, The Lancet.
[7] T. Mizushima,et al. Therapeutic effect of a new immunosuppressive agent, everolimus, on interleukin‐10 gene‐deficient mice with colitis , 2007, Clinical and experimental immunology.
[8] C. Bodemer,et al. Cutaneous Adverse Events in Renal Transplant Recipients Receiving Sirolimus-Based Therapy1 , 2005, Transplantation.
[9] E. Raymond,et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Koichiro Nakamura,et al. Thymus and activation-regulated chemokine in atopic dermatitis: Serum thymus and activation-regulated chemokine level is closely related with disease activity. , 2001, The Journal of allergy and clinical immunology.